Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q2 2022 · 10-Q
Revenue$125.07M$125.07M+2.8% vs Q2 2021 Net Income-$35.30M-$35.30MN/M vs Q2 2021 EPS Diluted-$0.28-$0.28N/M vs Q2 2021 Gross Profit$43,946,000−17.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Operating Cash Flowderived-$16,996,000N/M Free Cash Flowderived-$27,290,000N/M Margins · derivedGross margin35.1%−8.4 pt vs Q2 2021
Operating margin-31.7%−13.4 pt vs Q2 2021
Net margin-28.2%−90.6 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 9, 2022 · 40 d after period end